Références

1. NCI website ( http://www.nci.nih.gov )
2. InVs. Cas incidents de cancers et décès estimés par localisation et tranche d'âge, chez la femme en 2005. www.invs.sante.fr/surveillance/cancers/estimations_cancers/default.htm (consulté le 28.02.2008)
3. Exbrayat C. Col de l'utérus. In: Evolution de l'incidence, de la mortalité par cancer en France de 1978 à 2000. Remontet L, Buemi A, Velten M, Jougla E, Esteve J Eds. Institut de Veille Sanitaire, Paris, 2003. p107-112
4. Barrasso R, Guillemotonia A. Cervix and vagina: Diagnosis. In: Gross, Barrasso Eds. Human papillomavirus infection: A clinical atlas. Ullstein Mosby, 1997. p147–274.
5. Walboomers JMM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
6. Munoz N. Human papillomavirus and cancer: The epidemiological evidence. J Clin Virol 2000;19:1-5.
7. Pagliusi SR and Aguado MT. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23:569-578.
8. Wieland U, Pfister H. Papillomaviruses in human pathology: Epidemiology, pathogenesis and oncogenic role. In: Gross, Barrasso Eds. Human Papilloma Virus Infection: A clinical atlas. Ullstein Mosby; 1997. p1–18.
9. IARC Handbooks of Cancer Prevention. IARC Press; 2005. Chapter 4: Efficacy of screening. p163-199.
10. Peto J, Gilham C, Deacon J et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004;91:942-53
11. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
12. Bosch FX and de Sanjosé S. Chapter 1: Human papillomavirus and cervical cancer – Burden and Assessment of causality. J Natl Cancer Inst Monogr 2003;31:3-13.
13. Syrjänen K, Hakama M, Saarikoski S et al. Prevalence, incidence and estimated life-time risk of cervical human papilomavirus infections in a non selected Finninsh female population. Sex Transm Dis. 1990 Jan-Mar;17(1):15-9
14. Winer RL, Lee S-K, Hughes JP et al. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-226.
15. Agence Nationale d'Accréditation et d'Evaluation en Santé. Evaluation de l'intérêt de la recherche des papillomavirus humains (HPV) dans le dépistage des lésions précancéreuses et cancéreuses du col de l'utérus. Service évaluation économique. ANAES, 2004. 
16. Agence Nationale d'Accréditation et d'Évaluation en Santé. Clinical practice guidelines: Management of a patient with an abnormal cervical smear. 2002 update.
17. Goldie SJ, Kohli M, Grima D et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-615.
18. Beutner KR and Wiley DJ. Recurrent external genital warts: A literature review. Papillomavirus Rep 1997;8:69-74.
19. Maw RD, Reitano M and Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998;9:571-578
20. Stanley M. Genital Human Papillomavirus Infection-Current and prospective therapies. J Natl Cancer Inst Monogr 2003;31:117-124
21. Kyrgiou M, Koliopoulos G, Martin-Hirsch P et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: Systematic review and meta-analysis. Lancet 2006;367:489-498.
22. McDonald TW, Neutens JJ, Fischer LM et al. Impact of cervical intraepithelial neoplasia diagnosis and treatment on self-esteem and body image. Gynecol Oncol 1989;34:345-349.
23. Bernard HU. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 2005;32S:S1-6.
24. Munoz N, Bosch FX, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-285.
25. Clifford GM, Smith JS, Plummer M et al. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 2003;88:63-73.
26. Clifford GM, Smith JS, Aguado T et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A meta-analysis. Br J Cancer 2003;89:101-105.
27. Clifford GM, Rana RK, Franceschi S et al. Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-1164.
28. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001;11:598-604.
29. Anttila A, Ronco G, Clifford G et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004;91:935-941.
30. Rousseau A, Bohet P, Merlière J et al. Evaluation du dépistage organise et du dépistage individual du cancer du col de l'utérus: utilité des données de l'Assurance maladie. BEH 2002;19:81-83
31. Sawaya GF, McConnell KJ, Kulsingam SL et al. Risk of cervical cancer associated with extending the interval between cervical cancer screenings. N Engl J Med 2003;349:1501-1509.
32. Madeleine MM, Daling JR, Carter JJ et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst 1997;89:1516-1523.
33. Daling JR, Madeleine MM, Schwartz SM et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002;84:263-270.
34. http://www.hpa.org.uk/
35. McMillan A. The management of difficult anogenital warts. Sex Transm Inf 1999;75:192–194.
36. Clinical Effectiveness Group (Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). National guideline for the management of anogenital warts.